MESOBLAST LIMITED - Announcements

0.00%

$2.29

Market Cap $2.931B

Healthcare Biotechnology

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) accelerates commercialisation with positive Phase II results.

Announcements

Filter Results

All Price Sensitive Only

MSB	Material Announcement	PRICE SENSITIVE	05/12/24	112.64KB	Share
MSB	Pause in Trade	PRICE SENSITIVE	05/12/24	115.3KB	Share
MSB	FDA Grants Mesoblast RMAT Designation	PRICE SENSITIVE	05/12/24	196.86KB	Share
MSB	REVASCOR Improves Survival & Reduces Major Morbidity		03/12/24	205.8KB	Share
MSB	Becoming a substantial holder		21/11/24	1.87MB	Share
MSB	Results of Meeting		15/11/24	251.44KB	Share
MSB	Final Director's Interest Notice		15/11/24	265.82KB	Share
MSB	CEO Presentation to 2024 Annual General Meeting		15/11/24	2.24MB	Share
MSB	Mesoblast Chair Message to 2024 AGM		15/11/24	177.51KB	Share
MSB	Response to ASX Price Query	PRICE SENSITIVE	14/11/24	364.45KB	Share
MSB	Notification regarding unquoted securities - MSB		12/11/24	17.57KB	Share
MSB	Warrant Prospectus Related to Convertible Note Agreement		07/11/24	560.06KB	Share
MSB	Ceasing to be a substantial holder		05/11/24	1.22MB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/24	441.54KB	Share
MSB	Annual Report to Shareholders		17/10/24	4.25MB	Share
MSB	Notice of Annual General Meeting and Proxy Form		17/10/24	414.34KB	Share
MSB	Appendix 4G and Corporate Governance Statement		17/10/24	468.83KB	Share
MSB	Notification of cessation of securities - MSB		11/10/24	12.74KB	Share
MSB	Notification regarding unquoted securities - MSB		11/10/24	16.21KB	Share
MSB	Change in substantial holding		10/10/24	235.74KB	Share
MSB	Becoming a substantial holder		09/10/24	1.01MB	Share
MSB	Proposed issue of securities - MSB		30/09/24	16.48KB	Share
MSB	Mesoblast Option to Issue up to US$50m Convertible Notes	PRICE SENSITIVE	30/09/24	193.91KB	Share
MSB	Ceasing to be a substantial holder		27/09/24	1.44MB	Share
MSB	Becoming a substantial holder		17/09/24	1.07MB	Share
MSB	MSB Annual Financial Results and Operational Update	PRICE SENSITIVE	29/08/24	548.01KB	Share
MSB	Annual Financial Results Presentation	PRICE SENSITIVE	29/08/24	2.38MB	Share
MSB	Preliminary Final Report including Appendix 4E	PRICE SENSITIVE	29/08/24	2.53MB	Share
MSB	Mesoblast 2024 Full Year Financial Results Webcast		28/08/24	114.37KB	Share
MSB	Class Action Resolution	PRICE SENSITIVE	21/08/24	128.66KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/24	432.15KB	Share
MSB	FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L	PRICE SENSITIVE	23/07/24	185.89KB	Share
MSB	Confirmatory Phase 3 Back Pain Trial Actively Enrols		22/07/24	151.13KB	Share
MSB	Appendix 3Y for Philip Krause		12/07/24	198.24KB	Share
MSB	Notification regarding unquoted securities - MSB		12/07/24	16.26KB	Share
MSB	Notification of cessation of securities - MSB		12/07/24	12.8KB	Share
MSB	Change in substantial holding		12/07/24	147.76KB	Share
MSB	Mesoblast Resubmits BLA with FDA for Ryoncil Approval	PRICE SENSITIVE	09/07/24	178.36KB	Share
MSB	Mesoblast to File BLA for Ryoncil FDA Approval Next Week		01/07/24	157.33KB	Share
MSB	Mesoblast Corporate Presentation at Investor Conference		03/06/24	157.16KB	Share
MSB	Corporate Presentation		03/06/24	1.62MB	Share
MSB	Appendix 3Y for Eric Rose		10/05/24	215.42KB	Share
MSB	Appendix 3Y for Eric Rose		03/05/24	215.34KB	Share
MSB	Change in substantial holding		02/05/24	127.29KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/24	416.56KB	Share
MSB	Mesoblast Chair Transition		30/04/24	131.25KB	Share
MSB	Appendix 3Y for Jane Bell		16/04/24	171.94KB	Share
MSB	Application for quotation of securities - MSB		16/04/24	17.59KB	Share
MSB	Notification regarding unquoted securities - MSB		16/04/24	15.92KB	Share
MSB	Notification of cessation of securities - MSB		15/04/24	12.8KB	Share
MSB	Change in substantial holding		09/04/24	2.01MB	Share
MSB	Change in substantial holding		02/04/24	1.06MB	Share
MSB	FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA	PRICE SENSITIVE	26/03/24	159.39KB	Share
MSB	Pause in Trading	PRICE SENSITIVE	26/03/24	114KB	Share
MSB	Cleansing Notice		26/03/24	108.36KB	Share
MSB	Application for quotation of securities - MSB		22/03/24	14.19KB	Share
MSB	Change in substantial holding		20/03/24	1.37MB	Share
MSB	Proposed issue of securities - MSB		20/03/24	14.8KB	Share
MSB	Cleansing Notice		19/03/24	227.96KB	Share
MSB	Appendix 2A		18/03/24	344.46KB	Share
MSB	Proposed issue of securities - MSB		14/03/24	15.09KB	Share
MSB	Mesoblast Completes Placement and Entitlement Offer	PRICE SENSITIVE	14/03/24	159.66KB	Share
MSB	FDA Supports Accelerated Approval Pathway for Heart Failure	PRICE SENSITIVE	11/03/24	183.32KB	Share
MSB	MSB Q2 Financial Results and Operational Highlights	PRICE SENSITIVE	29/02/24	486.32KB	Share
MSB	Half Year Financial Results Presentation	PRICE SENSITIVE	29/02/24	1.7MB	Share
MSB	Half Year Report and Accounts (including Appendix 4D)	PRICE SENSITIVE	29/02/24	1.66MB	Share
MSB	Mesoblast 2024 Half Year Financial Results Webcast		26/02/24	113.58KB	Share
MSB	FDA Grants Orphan Drug Designation for Revascor	PRICE SENSITIVE	15/02/24	176.6KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/24	423.11KB	Share
MSB	FDA Grants Rare Pediatric Disease Designation for Revascor	PRICE SENSITIVE	19/01/24	181.5KB	Share
MSB	App 3Ys S Itescu,E Rose,J Swedish,B Burns,J Bell,P Facchina		15/01/24	339.51KB	Share
MSB	Notification regarding unquoted securities - MSB		15/01/24	27.4KB	Share
MSB	Notification of cessation of securities - MSB		15/01/24	23.21KB	Share
MSB	Appendix 3Y for Joseph Swedish		03/01/24	213.56KB	Share
MSB	Amended Appendix 3Gs for Unquoted Warrants		03/01/24	814.1KB	Share
MSB	Update on Institutional Placement and Entitlement Offer		28/12/23	139.29KB	Share
MSB	Appendix 3Ys- J Swedish,B Burns,J Bell,P Krause,P Facchina		28/12/23	525.98KB	Share
MSB	Appendix 2A		28/12/23	347.15KB	Share
MSB	Notification of cessation of securities - MSB		28/12/23	21.55KB	Share
MSB	Change of Director's Interest Notice - Silviu Itescu		12/12/23	199.23KB	Share
MSB	Institutional Placement Cleansing Notice		12/12/23	263.86KB	Share
MSB	Appendix 2A		11/12/23	375.53KB	Share
MSB	Information For Retail Shareholders	PRICE SENSITIVE	08/12/23	2.54MB	Share
MSB	Mesoblast Completes Institutional Allocation	PRICE SENSITIVE	05/12/23	197.91KB	Share
MSB	Entitlement Offer Cleansing Notice		04/12/23	168.57KB	Share
MSB	Appendix 3B Entitlement Offer and Placement		04/12/23	694.03KB	Share
MSB	Entitlement Offer and Placement Investor Presentation	PRICE SENSITIVE	04/12/23	2.06MB	Share
MSB	MSB Launches Entitlement Offer and Placement	PRICE SENSITIVE	04/12/23	292.56KB	Share
MSB	Trading Halt	PRICE SENSITIVE	01/12/23	217.16KB	Share
MSB	Amended Constitution		29/11/23	915.58KB	Share
MSB	Results of Meeting		28/11/23	187.13KB	Share
MSB	CEO Presentation to 2023 Annual General Meeting		28/11/23	1.89MB	Share
MSB	Mesoblast Chairman Message to 2023 AGM		28/11/23	181.09KB	Share
MSB	MSB Files for FDA Designations in Congenital Heart Disease		27/11/23	191.4KB	Share
MSB	Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial		22/11/23	174.07KB	Share
MSB	Mesoblast Corporate Presentation		15/11/23	1.68MB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/23	398.85KB	Share
MSB	Annual Report to Shareholders		30/10/23	3.92MB	Share
MSB	Notice of Annual General Meeting and Proxy Form		30/10/23	471.69KB	Share
MSB	Appendix 4G and Corporate Governance Statement		30/10/23	473.72KB	Share

MSB Material Announcement
05/12/24	PRICE SENSITIVE	112.64KB	Share
MSB Pause in Trade
05/12/24	PRICE SENSITIVE	115.3KB	Share
MSB FDA Grants Mesoblast RMAT Designation
05/12/24	PRICE SENSITIVE	196.86KB	Share
MSB REVASCOR Improves Survival & Reduces Major Morbidity
03/12/24		205.8KB	Share
MSB Becoming a substantial holder
21/11/24		1.87MB	Share
MSB Results of Meeting
15/11/24		251.44KB	Share
MSB Final Director's Interest Notice
15/11/24		265.82KB	Share
MSB CEO Presentation to 2024 Annual General Meeting
15/11/24		2.24MB	Share
MSB Mesoblast Chair Message to 2024 AGM
15/11/24		177.51KB	Share
MSB Response to ASX Price Query
14/11/24	PRICE SENSITIVE	364.45KB	Share
MSB Notification regarding unquoted securities - MSB
12/11/24		17.57KB	Share
MSB Warrant Prospectus Related to Convertible Note Agreement
07/11/24		560.06KB	Share
MSB Ceasing to be a substantial holder
05/11/24		1.22MB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
31/10/24	PRICE SENSITIVE	441.54KB	Share
MSB Annual Report to Shareholders
17/10/24		4.25MB	Share
MSB Notice of Annual General Meeting and Proxy Form
17/10/24		414.34KB	Share
MSB Appendix 4G and Corporate Governance Statement
17/10/24		468.83KB	Share
MSB Notification of cessation of securities - MSB
11/10/24		12.74KB	Share
MSB Notification regarding unquoted securities - MSB
11/10/24		16.21KB	Share
MSB Change in substantial holding
10/10/24		235.74KB	Share
MSB Becoming a substantial holder
09/10/24		1.01MB	Share
MSB Proposed issue of securities - MSB
30/09/24		16.48KB	Share
MSB Mesoblast Option to Issue up to US$50m Convertible Notes
30/09/24	PRICE SENSITIVE	193.91KB	Share
MSB Ceasing to be a substantial holder
27/09/24		1.44MB	Share
MSB Becoming a substantial holder
17/09/24		1.07MB	Share
MSB MSB Annual Financial Results and Operational Update
29/08/24	PRICE SENSITIVE	548.01KB	Share
MSB Annual Financial Results Presentation
29/08/24	PRICE SENSITIVE	2.38MB	Share
MSB Preliminary Final Report including Appendix 4E
29/08/24	PRICE SENSITIVE	2.53MB	Share
MSB Mesoblast 2024 Full Year Financial Results Webcast
28/08/24		114.37KB	Share
MSB Class Action Resolution
21/08/24	PRICE SENSITIVE	128.66KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
31/07/24	PRICE SENSITIVE	432.15KB	Share
MSB FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
23/07/24	PRICE SENSITIVE	185.89KB	Share
MSB Confirmatory Phase 3 Back Pain Trial Actively Enrols
22/07/24		151.13KB	Share
MSB Appendix 3Y for Philip Krause
12/07/24		198.24KB	Share
MSB Notification regarding unquoted securities - MSB
12/07/24		16.26KB	Share
MSB Notification of cessation of securities - MSB
12/07/24		12.8KB	Share
MSB Change in substantial holding
12/07/24		147.76KB	Share
MSB Mesoblast Resubmits BLA with FDA for Ryoncil Approval
09/07/24	PRICE SENSITIVE	178.36KB	Share
MSB Mesoblast to File BLA for Ryoncil FDA Approval Next Week
01/07/24		157.33KB	Share
MSB Mesoblast Corporate Presentation at Investor Conference
03/06/24		157.16KB	Share
MSB Corporate Presentation
03/06/24		1.62MB	Share
MSB Appendix 3Y for Eric Rose
10/05/24		215.42KB	Share
MSB Appendix 3Y for Eric Rose
03/05/24		215.34KB	Share
MSB Change in substantial holding
02/05/24		127.29KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
30/04/24	PRICE SENSITIVE	416.56KB	Share
MSB Mesoblast Chair Transition
30/04/24		131.25KB	Share
MSB Appendix 3Y for Jane Bell
16/04/24		171.94KB	Share
MSB Application for quotation of securities - MSB
16/04/24		17.59KB	Share
MSB Notification regarding unquoted securities - MSB
16/04/24		15.92KB	Share
MSB Notification of cessation of securities - MSB
15/04/24		12.8KB	Share
MSB Change in substantial holding
09/04/24		2.01MB	Share
MSB Change in substantial holding
02/04/24		1.06MB	Share
MSB FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
26/03/24	PRICE SENSITIVE	159.39KB	Share
MSB Pause in Trading
26/03/24	PRICE SENSITIVE	114KB	Share
MSB Cleansing Notice
26/03/24		108.36KB	Share
MSB Application for quotation of securities - MSB
22/03/24		14.19KB	Share
MSB Change in substantial holding
20/03/24		1.37MB	Share
MSB Proposed issue of securities - MSB
20/03/24		14.8KB	Share
MSB Cleansing Notice
19/03/24		227.96KB	Share
MSB Appendix 2A
18/03/24		344.46KB	Share
MSB Proposed issue of securities - MSB
14/03/24		15.09KB	Share
MSB Mesoblast Completes Placement and Entitlement Offer
14/03/24	PRICE SENSITIVE	159.66KB	Share
MSB FDA Supports Accelerated Approval Pathway for Heart Failure
11/03/24	PRICE SENSITIVE	183.32KB	Share
MSB MSB Q2 Financial Results and Operational Highlights
29/02/24	PRICE SENSITIVE	486.32KB	Share
MSB Half Year Financial Results Presentation
29/02/24	PRICE SENSITIVE	1.7MB	Share
MSB Half Year Report and Accounts (including Appendix 4D)
29/02/24	PRICE SENSITIVE	1.66MB	Share
MSB Mesoblast 2024 Half Year Financial Results Webcast
26/02/24		113.58KB	Share
MSB FDA Grants Orphan Drug Designation for Revascor
15/02/24	PRICE SENSITIVE	176.6KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
31/01/24	PRICE SENSITIVE	423.11KB	Share
MSB FDA Grants Rare Pediatric Disease Designation for Revascor
19/01/24	PRICE SENSITIVE	181.5KB	Share
MSB App 3Ys S Itescu,E Rose,J Swedish,B Burns,J Bell,P Facchina
15/01/24		339.51KB	Share
MSB Notification regarding unquoted securities - MSB
15/01/24		27.4KB	Share
MSB Notification of cessation of securities - MSB
15/01/24		23.21KB	Share
MSB Appendix 3Y for Joseph Swedish
03/01/24		213.56KB	Share
MSB Amended Appendix 3Gs for Unquoted Warrants
03/01/24		814.1KB	Share
MSB Update on Institutional Placement and Entitlement Offer
28/12/23		139.29KB	Share
MSB Appendix 3Ys- J Swedish,B Burns,J Bell,P Krause,P Facchina
28/12/23		525.98KB	Share
MSB Appendix 2A
28/12/23		347.15KB	Share
MSB Notification of cessation of securities - MSB
28/12/23		21.55KB	Share
MSB Change of Director's Interest Notice - Silviu Itescu
12/12/23		199.23KB	Share
MSB Institutional Placement Cleansing Notice
12/12/23		263.86KB	Share
MSB Appendix 2A
11/12/23		375.53KB	Share
MSB Information For Retail Shareholders
08/12/23	PRICE SENSITIVE	2.54MB	Share
MSB Mesoblast Completes Institutional Allocation
05/12/23	PRICE SENSITIVE	197.91KB	Share
MSB Entitlement Offer Cleansing Notice
04/12/23		168.57KB	Share
MSB Appendix 3B Entitlement Offer and Placement
04/12/23		694.03KB	Share
MSB Entitlement Offer and Placement Investor Presentation
04/12/23	PRICE SENSITIVE	2.06MB	Share
MSB MSB Launches Entitlement Offer and Placement
04/12/23	PRICE SENSITIVE	292.56KB	Share
MSB Trading Halt
01/12/23	PRICE SENSITIVE	217.16KB	Share
MSB Amended Constitution
29/11/23		915.58KB	Share
MSB Results of Meeting
28/11/23		187.13KB	Share
MSB CEO Presentation to 2023 Annual General Meeting
28/11/23		1.89MB	Share
MSB Mesoblast Chairman Message to 2023 AGM
28/11/23		181.09KB	Share
MSB MSB Files for FDA Designations in Congenital Heart Disease
27/11/23		191.4KB	Share
MSB Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial
22/11/23		174.07KB	Share
MSB Mesoblast Corporate Presentation
15/11/23		1.68MB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
31/10/23	PRICE SENSITIVE	398.85KB	Share
MSB Annual Report to Shareholders
30/10/23		3.92MB	Share
MSB Notice of Annual General Meeting and Proxy Form
30/10/23		471.69KB	Share
MSB Appendix 4G and Corporate Governance Statement
30/10/23		473.72KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $2.29		Change 0.000(0.00%)		Mkt cap ! $2.931B

Open	High	Low	Value	Volume
$2.26	$2.31	$2.25	$4.493M	1.965M

Buyers (Bids)

No.	Vol.	Price($)
1	13044	$2.28

Sellers (Offers)

Price($)	Vol.	No.
$2.29	4885	3

View Market Depth

No.	Vol.	Price($)
1	13044	2.280
5	56371	2.270
7	81639	2.260
26	130952	2.250
10	21431	2.240

Price($)	Vol.	No.
2.290	4885	3
2.300	59567	4
2.310	15489	4
2.320	50600	3
2.330	23472	4

Last trade - 16.14pm 12/08/2025 (20 minute delay)


Last $2.28		Change 0.000 ( 0.33 %)
Open	High	Low	Volume
$2.27	$2.31	$2.26	689025
Last updated 15.59pm 12/08/2025 ?

MSB (ASX) Chart

MESOBLAST LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories